(Q33340368)

25 July 2017

title

A phase II study of gemcitabine in gallbladder carcinoma (English)

1 reference

25 July 2017

main subject

gallbladder carcinoma

1 reference

J O Gallardo

1

1 reference

25 July 2017

B Rubio

2

1 reference

25 July 2017

M Fodor

3

1 reference

25 July 2017

L Orlandi

4

1 reference

25 July 2017

M Yáñez

5

1 reference

25 July 2017

C Gamargo

6

1 reference

25 July 2017

M Ahumada

7

1 reference

25 July 2017

publication date

1 October 2001

1 reference

25 July 2017

1 reference

25 July 2017

volume

12

1 reference

25 July 2017

issue

10

1 reference

25 July 2017

page(s)

1403-1406

1 reference

Gallbladder cancer in Chile: A report on 54 potentially resectable tumors

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012543223020

7 January 2021

Identifiers

DOI

10.1023/A:1012543223020

1 reference

25 July 2017

1 reference